Patent · US Active

6-(2,3-dihydro-1H-pyrido-[2,3-b][1,4]oxazin-7-yl)-N-(4-morpholinophenyl)imidazo[1,2-a] pyrazin-8-amine as a spleen tyrosine kinase inhibitor

US9212191B2 · kind B2 · utility

19Cited by

19References

7Claims

0Family size

Assignee

GILEAD CONNECTICUT, INC. · US

Inventors

Scott A. Mitchell · East Haven, US
Kevin S. Currie · North Branford, US

Key dates

Filing date	Jun 9, 2014
Grant date	Dec 15, 2015
Priority date	—
Expiry date	Jun 9, 2034

Classification

Technology area (CPC G)Physics
CPC primaryG01N2333/91205
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided are imidazopyrazine compounds, particularly including 6-(2,3-dihydro-1H-pyrido-[2,3-b][1,4]oxazin-7-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazine-8-amine, structure below, and methods and formulations for their use in inhibiting Spleen Tyrosine Kinase in treating conditions including B-cell lymphomas or leukemias and inflammatory conditions:

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.